Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jeremy K. Hon"'
Autor:
Mark A. Socinski, Isamu Okamoto, J. Orsini, Hiroshi Sakai, Hui Zhang, Ray D. Page, Jeremy K. Hon, Vera Hirsh, Markus F. Renschler
Publikováno v:
Journal of Thoracic Oncology. 9(1):83-90
Introduction:nab-Paclitaxel (nab-P) is approved, in the United States, in combination with carboplatin for the first-line treatment of advanced non–small-cell lung cancer, based on a randomized phase 3 trial of nab-P plus carboplatin (nab-P/C) vers
Autor:
Kathy Cutter, Marshall T. Schreeder, Robert O. Dillman, Elizabeth F. Connelly, Carol DePriest, Jeremy K. Hon
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 22:185-193
We conducted a multicenter, community-based phase II trial of PCR biochemotherapy (pentostatin 4 mg/m2, cyclophosphamide 600 mg/m2, and rituximab 375 mg/m2) every 3 weeks for up to 6 cycles in patients with chronic lymphocytic leukemia (CLL) or small
Autor:
J. R. Gray, F. Anthony Greco, John D. Hainsworth, L A Kalman, Jeremy K. Hon, Lisa H. Morrissey
Publikováno v:
Journal of Clinical Oncology. 20:2937-2942
PURPOSE: To provide long-term follow-up on the survival of patients with advanced non–small-cell lung cancer treated with paclitaxel/carboplatin-based regimens in a multicenter, community-based setting. PATIENTS AND METHODS: Between March 1995 and
Autor:
John D. Hainsworth, Sharlene Litchy, F. Anthony Greco, Howard A. Burris, Jeremy K. Hon, Joan B. Erland, Joseph E. Brierre
Publikováno v:
Cancer. 88:1353-1358
BACKGROUND Second-line chemotherapy for patients with nonsmall cell lung carcinoma has been ineffective due to the lack of activity of older agents following platinum-based therapy. This Phase II trial evaluated the feasibility, toxicity, and efficac
Autor:
Jeremy K. Hon, L A Kalman, Daniel C. Scullin, Howard A. Burris, A. A. Meluch, Joan B. Erland, John D. Hainsworth, Steven W. Smith, Lisa H. Morrissey, F. Anthony Greco
Publikováno v:
Cancer. 85:1269-1276
BACKGROUND The combination of paclitaxel and carboplatin is widely used in the treatment of patients with advanced nonsmall cell lung carcinoma. In this Phase I/II study the authors evaluated the feasibility, toxicity, and efficacy of adding a third
Autor:
Mark A. Socinski, Shaker R. Dakhil, Corey J. Langer, Markus F. Renschler, Ray D. Page, Hui Zhang, J. Orsini, Vera Hirsh, Jeremy K. Hon, Isamu Okamoto
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 24(2)
This analysis evaluates safety and efficacy in elderly (≥ 70 years old) versus younger patients enrolled in a phase III advanced non-small-cell lung cancer (NSCLC) trial.Untreated stage IIIB/IV patients with PS 0/1 were randomly assigned (1:1) to c
Autor:
J Brown, R. J. Belt, M. Thant, Jeremy K. Hon, Y P Maguire, Gary M. Clark, Richard M. Elledge, P Bartels, D. D. Von Hoff
Publikováno v:
Journal of Clinical Oncology. 13:419-423
PURPOSE To determine if a rapid 3H-uridine uptake assay using breast tumor cells from biopsy specimens could predict clinical response to fluorouracil (5FU) in patients with metastatic breast cancer. PATIENTS AND METHODS A double-blind prospective st
Autor:
Jeremy K. Hon, C. Farley, John D. Hainsworth, J. H. Barton, Marshall T. Schreeder, David R. Spigel, F. Anthony Greco
Publikováno v:
Cancer. 113(4)
BACKGROUND. The purpose of the current study was to evaluate the efficacy and toxicity of weekly bortezomib in the treatment of patients with recurrent/refractory multiple myeloma. METHODS. A total of 40 patients with multiple myeloma who had receive
Publikováno v:
Annals of Pharmacotherapy. 31:1475-1477
OBJECTIVE: To describe a possible case of ofloxacin-induced generalized tonic—clonic seizure. Although the etiology is unknown, ofloxacin most likely precipitated this patient's seizure threshold because of sepsis or secondary to drug accumulation
Autor:
Malcolm J. Moore, Jeffrey R. Infante, Werner Scheithauer, Sunil R. Hingorani, Xinyu Wei, E. Gabriela Chiorean, Thomas J. Ervin, Jeremy K. Hon, M. Biakhov, Daniel D. Von Hoff, Alfredo Romano, Ramesh K. Ramanathan, Colin D. Weekes, Josep Tabernero, Francis P. Arena, David Goldstein, Vinod Ganju
Publikováno v:
Journal of Clinical Oncology. 31:4059-4059
4059^ Background: In MPACT, pts who received nab-P + G vs G had improved overall survival (OS; median 8.5 vs 6.7 mo; HR 0.72; p= 0.000015). Here we assessed potential PFs of OS. Methods: 861 pts with MPC were randomized 1:1, stratified by region, pre